Skip to main content
2023 ACVIM Forum Main banner
Final Program


2023 Event Program
Icon Legend
This session is not on your agenda.
This session is on your agenda. Click again to remove it.
Presentation Icons
ACVIM Resident Research Award Eligible
ACVIM Resident Research Award Eligible
Additional Fees May Be Required
Additional Fees May Be Required
By Invite Only
By Invite Only
Capturing for On Demand
Capturing for On Demand
Cardiology Research Abstract Award Eligible
Cardiology Research Abstract Award Eligible
ERC Approved Lecture for ACVIM Residency
ERC Approved Lecture for ACVIM Residency
ePoster
ePoster
Livestream
Livestream
One Health
One Health
Pre-Registration Required
Pre-Registration Required
RACE-Approved
RACE-Approved
Research Abstract
Research Abstract
Specialty Symposium
Specialty Symposium
State-of-the-Art (SOTA) Presentation
State-of-the-Art (SOTA) Presentation
Veterinary Technician
Veterinary Technician
Back
Evaluation ViewAttendees 3

Small Animal Internal Medicine

GI14 - Serum Concentrations of Calprotectin, S100A12, and alpha1-proteinase Inhibitor in Dogs with Pancreatitis

Friday, June 16, 2023
8:15 AM – 8:30 AM ET
Location: PCC 105AB
CE: 0.25
Research Abstract
Abstract: Background: Miniature Schnauzers are predisposed to develop pancreatitis, with familial hypertriglyceridemia (HTG) being a potential risk factor. Diagnosing pancreatitis in dogs is currently based on the integration of serum canine specific pancreatic lipase (cPLI) concentration, clinical presentation, and diagnostic imaging findings.

Objective: To investigate markers of systemic inflammation and antiprotease action in dogs with pancreatitis.

Animals: Miniature Schnauzers (n=35) with suspected pancreatitis (serum cPLI >400 µg/L, clinical signs, abdominal imaging).

Methods: Calprotectin, S100A12, and α1-proteinase (α1PI) concentrations were measured in serum samples. These markers were evaluated for associations with patient characteristics, clinical presentation, risk factors for pancreatitis, and outcome.

Results: Serum calprotectin, S100A12, and α1PI concentrations were increased in 57%, 57%, and 58% of dogs, with moderate to strong correlations among these biomarkers. Dogs with the typical presentation of pancreatitis had significantly higher α1PI concentrations than dogs with an atypical clinical presentation (P=0.0110), and serum α1PI concentrations >1,579 mg/L distinguished both subgroups with 70% sensitivity and 100% specificity. No difference in serum calprotectin or S100A12 concentrations was seen, but presenting with fewer clinical signs was associated with higher serum calprotectin (P=0.0377) and S100A12 concentrations (P=0.0149) in dogs with a typical pancreatitis presentation. No other associations were detected with patient characteristics, risk factors for pancreatitis (e.g., HTG, medications), or outcome.

Conclusions: Biomarkers of systemic inflammation and antiprotease activity are commonly increased in Miniature Schnauzers with pancreatitis. Serum calprotectin and S100A12 have limited utility in differentiating pancreatitis presentations, whereas serum α1PI concentrations might prove to serve as a marker of disease severity.